Frank\u00adfurt a. M. \/ London \u2014 The inter\u00adna\u00adtio\u00adnal private equity firms Bain Capi\u00adtal and Cinven have signed a binding agree\u00adment to sell a majo\u00adrity stake in STADA Arznei\u00admit\u00adtel AG (\u201cSTADA\u201d) to CapVest Part\u00adners LLP (\u201cCapVest\u201d). Since the take\u00adover by the two PE compa\u00adnies, Stada has grown by nine percent annu\u00adally and now gene\u00adra\u00adtes annual sales of more than four billion euros. \u2014 The gene\u00adrics manu\u00adfac\u00adtu\u00adrer was conside\u00adred one of the hottest IPO candi\u00adda\u00adtes this year. <\/p>\n
Bain Capi\u00adtal and Cinven acqui\u00adred STADA in 2017 and subse\u00adquently delis\u00adted the company from the stock exch\u00adange. Since then, they have supported the manage\u00adment team in trans\u00adforming STADA from a tradi\u00adtio\u00adnal German gene\u00adrics manu\u00adfac\u00adtu\u00adrer into a leading, broad-based global health\u00adcare plat\u00adform with a stra\u00adte\u00adgic focus on the three areas of consu\u00admer health\u00adcare, gene\u00adrics and specialty phar\u00admaceu\u00adti\u00adcals. Under the owner\u00adship of Bain Capi\u00adtal and Cinven, STADA has increased its sales to over EUR 4 billion, achie\u00adved an average annual growth rate of 9 percent and more than doubled its EBITDA (adjus\u00adted earnings before inte\u00adrest, taxes, depre\u00adcia\u00adtion and amortization). <\/p>\n
Bain Capi\u00adtal and Cinven have supported STADA in over 25 targe\u00adted acqui\u00adsi\u00adti\u00adons to further expand its market presence in Europe and beyond. The most important acqui\u00adsi\u00adti\u00adons include the Nizoral brand from John\u00adson & John\u00adson, Walm\u00adark and port\u00adfo\u00adlios of various consu\u00admer health\u00adcare brands from Glax\u00adoS\u00admit\u00adh\u00adKline and Sanofi. Thanks to the invest\u00adments and exper\u00adtise of both compa\u00adnies, STADA is now one of the leading health\u00adcare and phar\u00admaceu\u00adti\u00adcal groups in Europe. <\/p>\n
CapVest as new part\u00adner with exten\u00adsive expe\u00adri\u00adence in health\u00adcare invest\u00adments. With exten\u00adsive indus\u00adtry know\u00adledge and a strong track record in health\u00adcare invest\u00adments, CapVest is the ideal part\u00adner to accom\u00adpany STADA in its next phase of growth. CapVest also shares the prin\u00adci\u00adples that have shaped STADA\u2019s
\nsuccess to date: respon\u00adsi\u00adble owner\u00adship, opera\u00adtio\u00adnal excel\u00adlence and long-term value creation. <\/p>\n
Upon comple\u00adtion of the tran\u00adsac\u00adtion, Bain Capi\u00adtal and Cinven intend to retain a mino\u00adrity stake in STADA \u2014 a clear sign of their confi\u00addence in the company\u2019s contin\u00adued growth poten\u00adtial and the exper\u00adtise of the manage\u00adment team.<\/p>\n
Peter Gold\u00adschmidt, CEO of STADA, said: \u201cBain Capi\u00adtal and Cinven have been excel\u00adlent part\u00adners on our jour\u00adney to become a global market leader in consu\u00admer health\u00adcare, gene\u00adrics and specialty phar\u00admaceu\u00adti\u00adcals. Their support and confi\u00addence in our vision has enab\u00adled us to acce\u00adle\u00adrate our growth, drive inno\u00adva\u00adtion and expand inter\u00adna\u00adtio\u00adnally. We look forward to buil\u00adding on our leading posi\u00adtion toge\u00adther with CapVest.\u201d<\/p>\n
Dr. Michael Siefke, Part\u00adner at Bain Capi\u00adtal<\/strong>, said: \u201cSince our invest\u00adment in 2017, we are proud to have accom\u00adpa\u00adnied STADA on its path to beco\u00adming a leading pharma plat\u00adform in Europe. Toge\u00adther with Cinven and the outstan\u00adding manage\u00adment team, we were able to scale the consu\u00admer health\u00adcare busi\u00adness, streng\u00adthen the gene\u00adrics busi\u00adness and expand the specialty phar\u00admaceu\u00adti\u00adcals segment. The successful exit demons\u00adtra\u00adtes the growth poten\u00adtial of the company and the great commit\u00adment of its employees.\u201d<\/p>\n Bruno Schick, Co-Mana\u00adging Part\u00adner and Head of DACH at Cinven<\/strong>, added: \u201cSTADA has deve\u00adlo\u00adped extre\u00admely well in recent years. Toge\u00adther with Bain Capi\u00adtal and the manage\u00adment team, we have supported STADA in shar\u00adpe\u00adning its stra\u00adte\u00adgic focus, expan\u00adding its inter\u00adna\u00adtio\u00adnal presence and inves\u00adt\u00ading heavily in inno\u00adva\u00adtion, digi\u00adta\u00adliza\u00adtion and opera\u00adtio\u00adnal excellence Jeffe\u00adries <\/strong>and Roth\u00adschild & Co<\/strong> are support\u00ading the tran\u00adsac\u00adtion as M&A advi\u00adsors. In addi\u00adtion, Bain and Cinven were advi\u00adsed on the tran\u00adsac\u00adtion by Morgan Stan\u00adley, JP Morgan, Gold\u00adman Sachs<\/strong> and Deut\u00adsche Bank<\/strong> in addi\u00adtion to their role as global IPO coor\u00addi\u00adna\u00adtors. Other advi\u00adsors included Kirk\u00adland & Ellis, EY, BCG <\/strong>and ERM<\/strong>. \u2014 Finan\u00adcial details of the tran\u00adsac\u00adtion were not disc\u00adlo\u00adsed. The closing is subject to the <\/p>\n About Cinven The manage\u00adment compa\u00adnies of the Cinven Funds, Cinven Capi\u00adtal Manage\u00adment (V) Gene\u00adral Part\u00adner Limi\u00adted, Cinven Capi\u00adtal Manage\u00adment (VI) Gene\u00adral Part\u00adner Limi\u00adted, Cinven Capi\u00adtal Manage\u00adment (VII) Gene\u00adral Part\u00adner Limi\u00adted and Cinven Capi\u00adtal Manage\u00adment (SFF) Gene\u00adral Part\u00adner Limi\u00adted, are each licen\u00adsed and regu\u00adla\u00adted by the Guern\u00adsey Financial About Bain Capital About STADA Arznei\u00admit\u00adtel AG Advi\u00adsor CAPVEST: Will\u00adkie Farr & Gallag\u00adher LLP<\/strong><\/p>\n The Will\u00adkie team compri\u00adsed part\u00adners David Arnold (Corporate\/PE, London), Dr. Nils R\u00f6ver (Corporate\/PE, Munich\/Hamburg), Andrew Gray (Corporate\/PE, London, all three lead), Dr. Kamyar Abrar, Georg Advi\u00adsor STADA: POELLATH advi\u00adsed the manage\u00adment of STADA in connec\u00adtion with the invest\u00adment by CapVest regar\u00adding the manage\u00adment parti\u00adci\u00adpa\u00adtion with the follo\u00adwing Munich team:<\/strong><\/p>\n Dr. Bene\u00addikt Hohaus (Part\u00adner, Manage\u00adment Parti\u00adci\u00adpa\u00adti\u00adons, M&A\/PE) About Will\u00adkie Farr & Gallag\u00adher LLP<\/strong><\/p>\n Will\u00adkie Farr & Gallag\u00adher LLP provi\u00addes leading legal solu\u00adti\u00adons to complex, busi\u00adness-criti\u00adcal issues that span markets and indus\u00adtries. Our appro\u00adxi\u00adm\u00adately 1,300 lawy\u00aders in 16 offices world\u00adwide provide inno\u00adva\u00adtive, prag\u00adma\u00adtic and sophisti\u00adca\u00adted legal services in around 45 areas of law. Frank\u00adfurt a. M. \/ London \u2014 The inter\u00adna\u00adtio\u00adnal private equity firms Bain Capi\u00adtal and Cinven have signed a binding agree\u00adment to sell a majo\u00adrity stake in STADA Arznei\u00admit\u00adtel AG (\u201cSTADA\u201d) to CapVest Part\u00adners LLP (\u201cCapVest\u201d). Since the take\u00adover by the two PE compa\u00adnies, Stada has grown by nine percent annu\u00adally and now gene\u00adra\u00adtes annual sales [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":56720,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-56721","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"\n
\n. The estab\u00adlish\u00adment of an agile manage\u00adment team and modern gover\u00adnance struc\u00adtures was central to this. With the new owner\u00adship struc\u00adture and CapVest by our side, we look forward to conti\u00adnuing STADA\u2019s jour\u00adney as a mino\u00adrity investor.\u201d <\/p>\n
\n<\/strong>
\n Cinven is a leading inter\u00adna\u00adtio\u00adnal private equity firm focu\u00adsed on buil\u00adding world-class global busi\u00adnesses. Cinven focu\u00adses on six sectors: Consu\u00admer, Busi\u00adness Services, Finan\u00adcial Services, Health\u00adcare, Indus\u00adtri\u00adals and TMT (Tech\u00adno\u00adlogy,
\nMedia and Tele\u00adcom\u00admu\u00adni\u00adca\u00adti\u00adons). Cinven has offices in major centers such as London, Frank\u00adfurt, Paris, Milan, Luxem\u00adbourg, Madrid, New York and Guern\u00adsey. The firm takes a respon\u00adsi\u00adble approach to its port\u00adfo\u00adlio compa\u00adnies, their employees, suppli\u00aders, local commu\u00adni\u00adties, the
\nenvi\u00adron\u00adment and society as a whole. <\/p>\n
\nServices Commis\u00adsion. Cinven Limi\u00adted, the advi\u00adser to the manage\u00adment compa\u00adnies of the Cinven funds, is a regu\u00adla\u00adted entity by the Finan\u00adcial Conduct Autho\u00adrity. In this press release, \u2018Cinven\u2019 means, indi\u00advi\u00addu\u00adally or coll\u00adec\u00adtively, as the context requi\u00adres, Cinven Holdings Guern\u00adsey Limi\u00adted, Cinven Part\u00adner\u00adship LLP and their respec\u00adtive part\u00adners (as defi\u00adned in the Compa\u00adnies Act 2006) and\/or funds mana\u00adged or advi\u00adsed by any of the foregoing.
\nhttp:\/\/www.cinven.com or <\/p>\n
\n<\/strong>
\n Foun\u00added in 1984, Bain Capi\u00adtal is one of the worl\u00add\u2019s leading private invest\u00adment firms. We are commit\u00adted to deli\u00adve\u00adring sustainable
\nresults for our inves\u00adtors, teams, compa\u00adnies and the commu\u00adni\u00adties in which we operate. As a private part\u00adner\u00adship, we lead with convic\u00adtion and a culture of colla\u00adbo\u00adra\u00adtion \u2014 advan\u00adta\u00adges that enable us to deve\u00adlop inno\u00adva\u00adtive invest\u00adment approa\u00adches, capi\u00adta\u00adlize on oppor\u00adtu\u00adni\u00adties and deli\u00adver excep\u00adtio\u00adnal results. Our global plat\u00adform invests in five core areas: Private Equity, Growth & Venture, Capi\u00adtal Solu\u00adti\u00adons, Credit & Capi\u00adtal Markets and Real Assets. We are repre\u00adsen\u00adted in 24 loca\u00adti\u00adons on four conti\u00adnents, employ more than 1,850 people and have assets under manage\u00adment of around USD 185 billion. \u2014 www.baincapital.com <\/p>\n
\n<\/strong>
\n STADA Arznei\u00admit\u00adtel AG is based in Bad Vilbel, Hesse. The company focu\u00adses on a three-pillar stra\u00adtegy consis\u00adting of consu\u00admer health\u00adcare products, gene\u00adrics and specialty phar\u00admaceu\u00adti\u00adcals. STADA Arznei\u00admit\u00adtel AG sells its products in more than 120 count\u00adries world\u00adwide. In finan\u00adcial year 2024, STADA achieved
\nGroup sales of \u20ac4,059 million and adjus\u00adted earnings before inte\u00adrest, taxes, depre\u00adcia\u00adtion and amortization. <\/p>\n
\nLinde (both Corporate\/PE, Frank\u00adfurt), Dr. Bettina Bokeloh, Dr. Patrick Meiisel (both Tax, Frank\u00adfurt), Matthias Schr\u00ada\u00adder (Liti\u00adga\u00adtion, Frank\u00adfurt), Rita Mitchell (Liti\u00adga\u00adtion, London), Rahul Saha (Anti\u00adtrust, London), Dr. Georg Weiden\u00adbach (Anti\u00adtrust, Frank\u00adfurt), Dr. Richard Roeder (Compli\u00adance, Munich), Anne Kleff\u00admann (Employ\u00adment, Munich), Coun\u00adsel Jacob Ahme (Corporate\/PE, Munich\/Hamburg), Henning Aufderhaar
\n(real estate law), Harry Nett\u00adlau (liti\u00adga\u00adtion), Martin Waskow\u00adski (employ\u00adment law, all Frank\u00adfurt), Alaric Green (anti\u00adtrust law, London) as well as asso\u00adcia\u00adtes Nils Bock, Patrick Kemper, Melina Terwes\u00adten, Jonas Volk, Sophie Wollen\u00adwe\u00adber (all corporate\/PE), Dr. Phil\u00adipp Stein\u00adhau\u00adsen (finance) Dr. Chris\u00adtian Wert\u00adh\u00adm\u00fcl\u00adler (real estate law), Sascha Wink\u00adler (employ\u00adment law, all Frank\u00adfurt), Fabiola Haas, Maxi\u00admi\u00adlian Schatz, Micheal Wies\u00adner, Dr. Zeno Wirtz (all corporate\/PE), Dr. Maxi\u00admi\u00adlian Schlutz (compli\u00adance) and Laurin Havlik (anti\u00adtrust law, all Munich).<\/p>\n
\nSilke Simmer, LL.M. (Coun\u00adsel, Manage\u00adment Parti\u00adci\u00adpa\u00adti\u00adons, M&A\/PE)
\nIda S\u00fc\u00df, LL.M. (UCLA) (Senior Asso\u00adciate, Manage\u00adment Parti\u00adci\u00adpa\u00adti\u00adons, M&A\/PE) <\/p>\n
\nwww.willkie.com<\/p>\n","protected":false},"excerpt":{"rendered":"